- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05245006
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
A First-in-Human, Pilot PET Imaging Study of 89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy in Men With Prostate Cancer
Study Overview
Status
Detailed Description
This single center imaging study involves one microdose of the imaging agent, followed by whole body PET imaging. Imaging data will be acquired in up to four PET studies to determine tumor and normal tissue uptake and dosimetry.
PRIMARY OBJECTIVES:
- To determine the optimal time point for imaging (based on analyzing the 4 scans of all participants using 89Zr-DFO-YS5 PET post-injection. (Cohort A)
- To determine the optimal antibody dose for imaging using 89Zr-DFO-YS5 PET. (Cohort B).
- To determine the sensitivity of metastatic lesion detection in mCRPC using 89Zr-DFO-YS5 PET as compared with conventional imaging.(Cohorts C & D)
SECONDARY OBJECTIVES:
- To determine the safety of 89Zr-DFO-YS5.
- To determine average organ uptake of 89Zr-DFO-YS5 (Cohort C & D).
- To descriptively report the patterns of intra-tumoral uptake of 89Zr-DFO-YS5 on whole body PET, including by site of disease, uptake by tumor type, inter-tumoral and inter-patient heterogeneity, and tumor-to-background signal (Cohorts C & D).
ARMS:
Cohort A: PET imaging data will be acquired up to four times to determine tumor and normal tissue uptake and dosimetry. The optimized scan time will be used for imaging in Cohorts B and C.
Cohort B: A dose of cold, non-radiolabeled antibody administered will be varied to determine the optimal antibody dose for image quality. The optimized antibody dose will be used in Cohort C and D. Participants will be followed for an additional 4-5 weeks after dose administration to assess for adverse events.
Cohort C: PET imaging will be acquired at the optimal time point and optimal antibody dose determined in Cohorts A & B.
Cohort D: PET imaging will be acquired at four time points using the antibody to enable calculation of tumor and organ dosimetry. This cohort enrolls concurrently with Cohort C.
All participants will be followed for up to 5 weeks after their first scan to assess for adverse events, and will be followed-up until progression. At the time of progression, participants will have the option to receive a repeat scan.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Maya Aslam
- Phone Number: 877-827-3222
- Email: Maya.Aslam@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco
-
Principal Investigator:
- Robert Flavell, MD, PhD
-
Contact:
- Phone Number: 877-827-3222
- Email: cancertrials@ucsf.edu
-
Contact:
- Maya Aslam
- Email: maya.aslam@ucsf.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must have histologically or cytologically confirmed metastatic, castration resistant prostate cancer (mCRPC).
- Age >=18 years
- Eastern Cooperative Oncology Group (ECOG) performance status < 2 (Karnofsky >60%).
Demonstrates adequate organ function as defined below:
- Total bilirubin <1.5 X upper limit of normal (ULN).
- Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase (SGOT)) <= 3 X institutional upper limit of normal (ULN).
- Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) <= 3 X institutional ULN.
- Creatinine clearance >= 60 mL/min, calculated using the Cockcroft-Gault equation.
- Ability to understand a written informed consent document, and the willingness to sign it.
- Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Exclusion Criteria:
- Patients who because of age, general medical, or psychiatric condition, or physiologic status cannot give valid informed consent.
- Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.
- Patients who have received the same antibody (YS5) earlier as part of therapy or detection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort B: 89Zr-DFO-YS5, YS5 antibody
Participants receive either a 20mg or 50mg dose of YS5 prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a single whole body PET scan at the optimal time determined in Cohort A. The optimal dose of unmodified YS5 antibody will be used in the following cohorts C & D. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
|
3 mCi will be administered intravenously
Other Names:
Imaging which combines a CT scan and a PET scan
Other Names:
Imaging which combines an MRI scan and a PET scan
Other Names:
20 or 50 mg administered intravenously
Other Names:
|
Experimental: Cohort C: 89Zr-DFO-YS5, Optimal dose YS5 antibody
Participants receive optimal dose of YS5 antibody prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a single whole body PET scan at the optimal time determined in Cohort A. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
|
3 mCi will be administered intravenously
Other Names:
Imaging which combines a CT scan and a PET scan
Other Names:
Imaging which combines an MRI scan and a PET scan
Other Names:
20 or 50 mg administered intravenously
Other Names:
|
Experimental: Cohort D: 89Zr-DFO-YS5, Optimal dose YS5 antibody, Multiple Scans
Participants will receive optimal dose of YS5 prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a series of whole body PET scans performed at 1-4 hours, approximately 20-28 hours, 48-96 hours, and 120-168 hours post injection for up to 4 scans total.
Participants in have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
|
3 mCi will be administered intravenously
Other Names:
Imaging which combines a CT scan and a PET scan
Other Names:
Imaging which combines an MRI scan and a PET scan
Other Names:
20 or 50 mg administered intravenously
Other Names:
|
Experimental: Cohort A: 89Zr-DFO-YS5
Participants receive one dose of 89Zr-DFO-YS5 up to 3 millicurie (mCi), and undergo a whole body PET performed at 1-4 hours, approximately 20-28 hours, 48-96 hours, and 120-168 hours post injection for up to 4 scans total.
The optimized scan time will be used for imaging in cohorts B and C. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
|
3 mCi will be administered intravenously
Other Names:
Imaging which combines a CT scan and a PET scan
Other Names:
Imaging which combines an MRI scan and a PET scan
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optimal time point for imaging using 89Zr-DFO-YS5 PET post-injection (Cohort A)
Time Frame: Up to 7 days
|
For Cohort A, the optimal time point will be selected based on optimal maximun Standardized uptake value (SUVmax) of metastatic lesions, and ratio of SUVmax to blood pool.
Due to the limited samples, the investigator will use all available lesions without considering the location of the lesions or the possible intra-correlation of the lesions from the same participant.
|
Up to 7 days
|
Optimal antibody dose for imaging using 89Zr-DFO-YS5 PET (Cohort B)
Time Frame: Up to 7 days
|
For Cohort B, the optimal dose of antibody will be selected based on the optimal SUVmax of metastatic lesions, and ratio of SUVmax to blood pool.
Due to the limited samples, the investigator will use all available lesions without considering the location of the lesions or the possible intra-correlation of the lesions from the same participant.
|
Up to 7 days
|
Proportion of participants with metastatic lesions accurately detected in mCRPC using 89Zr-DFO-YS5 PET (sensitivity) (Cohort C & D)
Time Frame: Up to 24 months
|
Sensitivity is the probability that a test will indicate disease among those with the actual disease: True Positive / (True Positive + False Negative).
Lesions will be graded on a semi-quantitative scale ranging from 1-5 as is common for 89Zr-antibody human imaging studies (1 = no uptake, 2 = probably no uptake, 3 = equivocal, 4 = probably positive, 5 = definitely positive).
Using as a cut-off to 4 or 5 on the semi-quantitative scale, the sensitivity of 89Zr-DFO-YS5 PET will be descriptively reported on a lesion-per-lesion basis, using as reference standard staging scans including CT or MRI of the chest/abdomen/pelvis and whole body bone scan.
The sensitivity estimate will be based on lesion level without considering the location of the lesions or the possible intra-correlation of the lesions from the same patient.
|
Up to 24 months
|
Median SUVmax (Cohort C & D)
Time Frame: Up to 24 months
|
The median and range of SUVmax across all metastatic lesions per participant will be descriptively reported using mediastinal blood pool and normal organ as background uptake values will be reported with range of SUVmax.
|
Up to 24 months
|
Average SUVmax (SUVmax-ave) (Cohort C & D)
Time Frame: Up to 24 months
|
The average SUVmax-ave across all metastatic lesions per participant will be descriptively reported using mediastinal blood pool and normal organ as background uptake values for all cohorts will be reported with 95% confidence intervals
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with treatment-related Adverse Events
Time Frame: Up to 3 weeks after last dose administration, approximately 35 days
|
The frequency and severity of adverse events following Zr-DFO-YS5 injection will be descriptively reported, using CTCAE version 5.0
|
Up to 3 weeks after last dose administration, approximately 35 days
|
Average organ uptake of 89Zr-DFO-YS5 (Cohort C & D)
Time Frame: Up to 24 months
|
Average organ uptake of 89Zr-DFO-YS5 on PET will be estimated.
|
Up to 24 months
|
Intra-tumoral uptake of 89Zr-DFO-YS5 by tumor type (Cohort C & D)
Time Frame: Up to 24 months
|
The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported
|
Up to 24 months
|
Intra-tumoral uptake of 89Zr-DFO-YS5 by Site of Disease (Cohort C & D)
Time Frame: Up to 24 months
|
The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported
|
Up to 24 months
|
Inter-tumoral heterogeneity (Cohort C & D)
Time Frame: Up to 24 months
|
The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported to assess for Inter-tumoral heterogeneity.
|
Up to 24 months
|
Inter-participant heterogeneity (Cohort C & D)
Time Frame: Up to 24 months
|
The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported to assess for Inter-participant heterogeneity
|
Up to 24 months
|
Tumor-to-background signal (Cohort C & D)
Time Frame: Up to 24 months
|
The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert Flavell, MD, PhD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 209210
- NCI-2022-01310 (Registry Identifier: NCI Clinical Trials Reporting Program (CTRP))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
Clinical Trials on 89Zr-DFO-YS5
-
Robert Flavell, MD, PhDNational Cancer Institute (NCI)RecruitingMultiple Myeloma | Plasma Cell MyelomaUnited States
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.Completed
-
Telix International Pty LtdRecruitingSoft Tissue Sarcoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Glioblastoma Multiforme | Non Small Cell Lung Cancer | Cholangiocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma and other conditionsUnited States
-
Telix International Pty LtdCompletedClear Cell Renal Cell CarcinomaUnited Kingdom, United States, Australia, Turkey, Netherlands, Belgium, Canada, France
-
Telix International Pty LtdCompletedCarcinoma, Renal Cell | Clear Cell Renal Cell CarcinomaJapan
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
Telix Pharmaceuticals (Innovations) Pty LimitedAvailable
-
Université de SherbrookeEli Lilly and Company; Chorus Wellness Inc.; AL-S Pharma AGRecruitingAmyotrophic Lateral SclerosisCanada
-
Robert Flavell, MD, PhDSuspended
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingDLBCL | Large B-cell LymphomaUnited States